Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - dorzolamide hydrochloride,timolol maleate -

Irska - angleščina - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - dorzolamide; timolol - eye drops, solution - 20 mg/ml+5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations

Kanada - angleščina - Health Canada

aa pharma inc - timolol maleate - tablet - 5mg - timolol maleate 5mg - beta-adrenergic blocking agents

Kanada - angleščina - Health Canada

aa pharma inc - timolol maleate - tablet - 10mg - timolol maleate 10mg - beta-adrenergic blocking agents

Kanada - angleščina - Health Canada

aa pharma inc - timolol maleate - tablet - 20mg - timolol maleate 20mg - beta-adrenergic blocking agents

Kanada - angleščina - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution (extended release) - 0.25% - timolol (timolol maleate) 0.25% - beta-adrenergic agents

Kanada - angleščina - Health Canada

sandoz canada incorporated - timolol (timolol maleate) - solution (extended release) - 0.5% - timolol (timolol maleate) 0.5% - beta-adrenergic agents

Združene države Amerike - angleščina - NLM (National Library of Medicine)

trigen laboratories, llc - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - hypertension timolol maleate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. myocardial infarction timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. migraine timolol is indicated for the prophylaxis of migraine headache. timolol maleate is contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see warnings); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see warnings); cardiogenic shock; hypersensitivity to this product.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

medsource pharmaceuticals - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

akorn - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - dorzolamide 20 mg in 1 ml - dorzolamide hydrochloride-timolol maleate is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target iop determined after multiple measurements over time). the iop-lowering of dorzolamide hydrochloride-timolol maleate administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see clinical studies (14)]. dorzolamide hydrochloride-timolol maleate is contraindicated in patients with bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease [see warnings and precautions (5.1)] . dorzolamide hydrochloride-timolol maleate is contraindicated in patients with sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock [see warnings and precautions (5.2)] . do